Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Steatohepatitis (NASH)

NCT04702490 is registered in ClinicalTrials.gov with Metacrine, Inc. as lead sponsor.

NCT NCT04702490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04702490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
Metacrine, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
December 15, 2020
Completion date
June 30, 2022
Enrollment
120 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes type 2, fatty liver, fatty liver, nonalcoholic, nafld, nash, nash - nonalcoholic steatohepatitis, type 2 diabetes